A phase I/IIa, single-centre, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study with a safety run-in period to assess the safety and efficacy of topical XZ.700 in patients with mild to moderate atopic dermatitis
Latest Information Update: 16 Aug 2021
At a glance
- Drugs XZ 700 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Micreos
Most Recent Events
- 22 Sep 2020 According to a Micreos media release, first patient has been enrolled in the trial. The company expects to finish the study and report the results towards the end of 2021.
- 22 Sep 2020 Status changed from planning to recruiting, according to a Micreos media release.
- 16 Apr 2019 New trial record